Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clinuvel Pharmaceuticals Ltd (CUV.AX)

Clinuvel Pharmaceuticals Ltd (CUV.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Clinuvel Pharmaceuticals Ltd 535 Bourke Street Level 11 Melbourne VIC 3000 AUS

https://www.clinuvel.com P: +61 396604900 F: +61 396604999

Description:

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Key Statistics

Overview:

Market Capitalization, $K 774,103
Shares Outstanding, K 50,104
Annual Sales, $ 78,321 K
Annual Net Income, $ 30,605 K
% of Institutional Shareholders 12.24%

Growth:

1-Year Return -16.39%
3-Year Return -48.25%
5-Year Return -55.38%
5-Year Revenue Growth 25.17%
5-Year Earnings Growth 17.22%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm 0.57
EPS Growth vs. Prev Year 0.47%
Annual Dividend Rate, $ 0.05
Annual Dividend Yield 0.32%
Most Recent Dividend 0.050 on 09/05/23
Next Ex-Dividends Date 09/05/23
Dividend Payable Date 09/20/23
Dividend Payout Ratio 8.73%
Most Recent Split 1-10 on 11/12/10

CUV.AX Ratios

Ratio
Price/Earnings ttm 26.96
Price/Earnings forward 18.76
Return-on-Equity % 18.97%
Return-on-Assets % 16.21%
Profit Margin % 39.08%
Debt/Equity 0.00
Price/Sales 10.02
Price/Book 4.33
Book Value/Share 3.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar